|
Management
The management team is a collection of experienced
pharmaceutical executives, proven entrepreneurs, and world class
scientists. Having worked together in the past, they have recently come
together to build Yaupon Therapeutics into a successful enterprise.
Robert Alonso, President & CEO is a
seasoned executive with 15 years of domestic and international
pharmaceutical experience in licensing, drug development and marketing.
He has held management positions for large multi-nationals such as Merck
and Hofmann La Roche as well as biotech start-ups with Layton Bioscience.
Mr. Alonso has run a $200 million infectious disease franchise and he has
closed over 15 licensing deals. Mr. Alonso has an MBA from F.W. Olin
Graduate School at Babson College.
Peter Crooks, Ph.D., Chief Scientific Officer, is an
internationally recognized expert in medicinal chemistry with extensive
experience in drug discovery and development. He is full professor and an
Endowed Chair in the Division of Pharmaceutical Sciences, University of
Kentucky and works part-time with Yaupon. Dr. Crooks has authored over
500 papers and holds more than 70 patents in the area of drug discovery.
He is the recipient of numerous awards. Dr. Crooks received his B.S.,
M.S., and Ph.D. degrees from the University of Manchester, U.K.
Thomas P. Hess, CPA, Senior Vice President, Finance,
and Chief Financial Officer, is a seasoned financial
executive with 20 years of domestic and international experience. Prior
to joining Yaupon Therapeutics, Mr. Hess was the Vice President, Finance
and Chief Financial Officer of Adolor Corporation from 2005 to 2008 where
his responsibilities included investor relations, SEC reporting and cash
management. From 2003 until joining Adolor Corporation, Mr. Hess was
Corporate Controller of Vicuron Pharmaceuticals, Inc, a biopharmaceutical
company that was acquired by Pfizer I nc. in 2005 for $1.9 billion. From
2000 until 2003, Mr. Hess was Controller of Innovative Solutions and
Support, Inc., a manufacturer of high tech avionics equipment. Prior to
joining Innovative Solutions and Support, Inc., Mr. Hess was with KPMG
LLP for ten years in various positions, including as a senior manager.
Mr. Hess has a Bachelor of Science in accounting from Pennsylvania State
University and a Masters of Business Administration in Finance from the
University of Pittsburgh.
Martin
Stogniew, Ph.D., Chief
Technology Officer, brings 28 years
of senior executive experience in the pharmaceutical industry. He has been responsible for all areas
of domestic and international drug development, including proprietary, generic,
over the counter drugs, and nutritional supplements. Mr. Stogniew has made significant
contributions to eight New Drug Application approvals by the FDA,
twenty-six US patents issued, and three major M&A deals. Most recently he was Executive Vice
President, Chief Technology Officer of Prestwick Pharmaceuticals and was
accountable for all technical and regulatory diligence during the sale of
the company to Biovail for $150 M.
Previously he was Executive Vice President, Scientific Affairs and
Executive Officer for Vicuron Pharmaceuticals where he played an integral
part in the sale to Pfizer for $1.9 B.
Prior to Vicuron he was Vice President, Pharmaceutical Sciences
and Corporate Officer for US Bioscience, which he helped sell for $492
M. Mr. Stogniew completed a post
doctoral fellowship at The Johns Hopkins University, School of Medicine,
earned a Ph.D. in Medicinal Chemistry from the University of Maryland and
received a B.S. in Pharmacy with honors from the University of Maryland.
Philip S. Schein, MD, DSc, FRCP,
is widely
regarded as a leading international authority in the treatment of cancer.
Currently he a Visiting Professor in Cancer Pharmacology, University of
Oxford and as President of The Schein Group, which provides consultative
services to the pharmaceutical industry. Dr. Schein served as a Senior
Investigator and Head of the Clinical Pharmacology Section of the
Medicine Branch, National Cancer Institute. His next appointment was at
the Georgetown University School of Medicine in Washington, DC, as
Professor of Medicine and Pharmacology, Chief of Medical Oncology and
Scientific Director of the Vincent T. Lombardi Cancer Research Center.
Subsequently he served as Vice President of Worldwide Clinical Research
and Development, and Director of the Laboratory of Molecular Oncology,
SmithKline & French Laboratories, where he had responsibility for all
SK&F clinical research and development activities. In 1987 Dr. Schein founded U.S.
Bioscience, a publically-traded pharmaceutical company focused on cancer
and AIDS, and while serving as Chairman and CEO he took three products,
Ethyol, Hexalen and Neutrexin, through development and regulatory
approval in the US, Europe, Canada and other countries. Dr. Schein has
held major positions in the field of Medical Oncology. He has served as
President of the American Society of Clinical Oncology and he has chaired
the Food and Drug Administration's Oncologic Drugs Advisory Committee. He
has served as a member of the Board of Directors on the American Board of
Internal Medicine, where he chaired the Medical Oncology Committee. He
was appointed by President Clinton to the National Cancer Advisory Board.
He has also served as co-Chairman of the Gastrointestinal Cancer Tumor
Study Group and was a founding member of the Japan-American,
French-American Agreement and Pan American Health Organization-US
Agreements on Cancer Research. In 1984, in a survey of department
chairmen and clinical-program chiefs at 87 medical schools, Dr. Schein
was ranked as one of the 120 best doctors in America, and one of four
listed in Oncology. He has
authored over 350 articles and texts relating to basic and clinical
cancer research and drug development, and has been awarded 11 patents. He is a recipient of numerous
scientific and medical awards including the Harvey W. Wiley Medal from
the FDA and the Wainwright Award for Excellence in Medical Education. Dr.
Schein is a Fellow of the Royal College of Physicians of London and the
Royal College of Physicians and Surgeons at Glasgow. While serving as CEO
of U.S. Bioscience he was the 1992 recipient of the Delaware Valley's
Entrepreneur of the Year Award in the "Emerging Company"
category, and in 1995 the region’s 3rd Annual Enterprise Awards
designated U.S. Bioscience the “Technology Transfer Company of the
Year.” He has been awarded a
Honorary Doctor of Science degree from Rutgers University and a Doctorate
Honoris Causa from the National University of Rosario, Argentina. He serves on the Board of Directors of
Medicis, and on the scientific advisory boards of several companies in
the biotechnology/pharmaceutical industry.
Office
Address:
Radnor, PA
259 North Radnor-Chester Road, Suite 205
Radnor, PA 19087
P 610-975-9290
F 610-975-9012
For additional information about Yaupon Therapeutics,
please email us at info@yaupontherapeutics.com
|
